APS is classified according to the 2023 ACR/EULAR classification criteria by at least one positive antiphospholipid antibody (aPL), followed by additive weight criteria grouped into six clinical domains (macrovascular arterial thrombosis, macrovascular venous thromboembolism, microvascular, cardiac valve, obstetric and hematologic) and two laboratory domains (anticardiolipin [aCL] and/or anti–β2-glycoprotein I antibodies, and lupus anticoagulant functional coagulation assays)4. This evidence concerns the gene ACLY and autoimmune polyendocrinopathy.